Showing 2,461 - 2,480 results of 18,177 for search 'significantly ((((greater decrease) OR (((we decrease) OR (nn decrease))))) OR (a decrease))', query time: 0.73s Refine Results
  1. 2461

    Exclusion and enrollment summary from NHANES. by Lu Han (151620)

    Published 2025
    “…Individuals under 30 showed no significant differences. A unit increase below 9.30 in Log2-PMR reduced HCV risk by 0.60-fold. …”
  2. 2462

    The epidemiology and gene mutation characteristics of pyrazinamide-resistant <i>Mycobacterium tuberculosis</i> clinical isolates in Southern China by Nan Wang (21935)

    Published 2025
    “…This difference in the <i>rpsA</i> mutation rate was statistically significant (<i>P = 0.001</i>, chi-square test). …”
  3. 2463

    Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer by Jiaxing Li (113609)

    Published 2025
    “…Herein, we reported an effective and selective PRMT7 inhibitor, <b>A33</b>, which was obtained through structural optimization and exhibited potent anti-PCa efficacy in vitro and in vivo. …”
  4. 2464

    Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer by Jiaxing Li (113609)

    Published 2025
    “…Herein, we reported an effective and selective PRMT7 inhibitor, <b>A33</b>, which was obtained through structural optimization and exhibited potent anti-PCa efficacy in vitro and in vivo. …”
  5. 2465

    Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer by Jiaxing Li (113609)

    Published 2025
    “…Herein, we reported an effective and selective PRMT7 inhibitor, <b>A33</b>, which was obtained through structural optimization and exhibited potent anti-PCa efficacy in vitro and in vivo. …”
  6. 2466

    Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer by Jiaxing Li (113609)

    Published 2025
    “…Herein, we reported an effective and selective PRMT7 inhibitor, <b>A33</b>, which was obtained through structural optimization and exhibited potent anti-PCa efficacy in vitro and in vivo. …”
  7. 2467

    The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    “…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”
  8. 2468

    The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    “…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”
  9. 2469

    CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    “…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”
  10. 2470

    Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    “…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”
  11. 2471

    The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    “…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”
  12. 2472

    The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    “…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”
  13. 2473
  14. 2474
  15. 2475
  16. 2476
  17. 2477
  18. 2478
  19. 2479

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  20. 2480

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”